Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.019

€0.019

-2.560%
-0.0005
-2.560%
-
 
19.07.24 / Frankfurt WKN: A2AE98 / Name: Shield / Stock / Other Specialty Retailers / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Shield Therapeutics PLC Stock

A loss of -2.560% shows a downward development for Shield Therapeutics PLC.

Pros and Cons of Shield Therapeutics PLC in the next few years

Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Shield Therapeutics PLC vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Shield Therapeutics PLC -2.560% -2.564% -19.149% -77.647% -72.857% -95.887% -98.348%
Pets At Home Group Ls 1 -0.640% 0.273% 2.515% -18.525% -1.185% -32.697% -
Card Factory plc 1.500% 4.152% 7.500% 9.455% -3.834% 79.701% -
Natural Grocers By Vit. Cot. -1.800% 2.830% 16.578% 91.228% 52.448% 138.251% 157.714%

News

Hardman & Co: Shield Therapeutics (STX): Cash management is key
Hardman & Co: Shield Therapeutics (STX): Cash management is key
Hardman & Co: Shield Therapeutics (STX): Cash management is key
2 Beaten-Down Stocks That Could Make You Richer: https://g.foolcdn.com/editorial/images/768265/pharmacist-talking-to-patient.jpg
2 Beaten-Down Stocks That Could Make You Richer

Becoming richer by investing in stocks usually doesn't happen overnight. It takes years -- sometimes decades -- of patience and holding on to shares of companies that aren't always performing as